Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Cigna Corp.
PET scans and CSF testing to confirm the presence of amyloid beta, and reimbursement, are expected to be early hurdles for launching aducanumab in Alzheimer's.
The first disease modifying drug for Alzheimer's disease will be priced at a $56,000 a year for an average weight patient, setting the drug up to be a mega blockbuster if Biogen can get it reimbursed.
Study will examine prior authorization and other access restrictions at 15 of the largest US commercial payers for a group of 27 drugs.
Study will look at prior authorization, step therapy and required medication switching for drugs considered to be reasonably priced.